Fresh From the Bench: Latest Precedential Patent Case

N
Nika Aldrich
Schwabe Williamson & Wyatt
January 8, 2024PTAB1 min read

Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.

CASE OF THE WEEK

Dexcom, Inc. v. Abbott Diabetes Care, Inc., Appeal No. 2023-1795 (Fed. Cir. Jan. 3, 2024)

In our Case of the Week, the Court of Appeals for the Federal Circuit affirmed a district court’s denial of DexCom’s motion to preliminarily enjoin Abbott from proceeding with its inter partes review challenges to DexCom’s patents, based on a “no challenge” provision in a prior settlement agreement between the parties.

After previous patent litigation between the parties, DexCom and Abbott had entered into a settlement agreement that included, among other things, a mutual covenant not to “Challenge” each other’s patents for a certain period of time—with “Challenge” defined to include IPR proceedings before the Patent Trial and Appeal Board (“PTAB”). A forum selection clause specified the U.S. District Court for the District of Delaware as the exclusive jurisdiction for disputes.

READ MORE

Editors:

Nika AldrichIP Litigation Group LeaderSchwabe, Williamson & Wyatt, P.C.

Jason A. WrubleskiShareholder

Contributors:

Tyler Hall, Associate

More insights

Data: FDA Orange & Purple Books · prosecution & litigation metadata · read-only.